Your session is about to expire
← Back to Search
ADI-PEG 20 + Gemcitabine + Docetaxel for Lung Cancer
This trial tests a 3-drug combo to treat lung cancer that has progressed on frontline treatment; first, a phase I will test different doses, then phase II will use the recommended dose to assess efficacy.
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You had skin cancer (basal cell or squamous cell carcinoma) that was removed with surgery only.You are currently taking any experimental medications.You have previously been treated with ADI-PEG 20 or gemcitabine, but prior treatment with docetaxel is allowed.You have had allergic reactions to drugs that are similar to ADI-PEG 20, gemcitabine, or pegylated compounds used in the study.You have a history of seizures that are not caused by your cancer.You have moderate or severe nerve damage (neuropathy).You have advanced stage lung cancer that has spread and did not respond to initial treatment. Your doctor thinks you are suitable for treatment with gemcitabine and docetaxel.You have had a previous cancer, but there are some types of cancer that are allowed.You have other types of tumors that have been discussed with the study doctor.You have brain metastases that have not been treated or are not stable. If you have received treatment for your brain metastases and they are not getting worse, you can still participate in the study.If you have a certain type of lung cancer without a specific gene mutation, you must have already received a certain type of treatment as your first option.
- Group 1: Phase I: ADI-PEG + gemcitabine + docetaxel
- Group 2: Phase II Non-small cell lung cancer: ADI-PEG + gemcitabine + docetaxel
- Group 3: Phase II Small cell lung cancer: ADI-PEG + gemcitabine + docetaxel
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are patients currently being signed up for this clinical trial?
"The clinical trial in question is no longer recruiting patients, as indicated by its last update on November 14th, 2022. However, out of the 2210 other trials seeking participants, this one was initially posted most recently on January 31st, 2023."
Share this study with friends